Glaukos price target raised to $83 from $67 at BTIG

BTIG raised the firm’s price target on Glaukos to $83 from $67 and keeps a Buy rating on the shares. The firm is modeling Q2 revenue of $72M, and tells investors in a research note that results are “highly beatable” given the seasonal improvements expected in the glaucoma market coupled with the company’s easiest comps of the year.